Loading...
Loading...
NEW YORK, NY · CIK 0001263508
Portfolio Value
$11.44B
Positions
122
New
7
Increased
23
Decreased
10
Sold Out
6
BAKER BROS. ADVISORS LP (NEW YORK, NY) reported a portfolio value of $11.44B across 122 positions in their Q2 2017 SEC 13F filing (period ending 2017-06-30). The top 10 positions account for 87.7% of the portfolio.
Top 30 holdings by portfolio weight. Block width = holding percentage. Green = new/increased, red = reduced, gray = unchanged.
| # | Stock | Value↓ | Weight | Change |
|---|---|---|---|---|
| 1 | INCYIncyte Corporation | $4.30B | 37.57% | +0.1% |
| 2 | SGENEURSeattle Genetics, Inc. | $2.37B | 20.68% | +0.0% |
| 3 | ALXNAlexion Pharmaceuticals, Inc. | $1.04B | 9.10% | +30.7% |
| 4 | ACADACADIA Pharmaceuticals Inc. | $720.11M | 6.30% | - |
| 5 | BMRNBioMarin Pharmaceutical Inc. | $536.35M | 4.69% | +22.9% |
| 6 | GHDXGenomic Health, Inc. | $448.54M | 3.92% | +0.1% |
| 7 | DBV Technologies S.A. | $196.75M | 1.72% | - |
| 8 | ONCBeiGene, Ltd. | $165.29M | 1.45% | - |
| 9 | Aquinox Pharmaceuticals, Inc. | $153.84M | 1.34% | - |
| 10 | AKAOQAchaogen, Inc. | $104.40M | 0.91% | +4.8% |
| Stock | Value | Shares |
|---|---|---|
| BDQMAlbireo Pharma, Inc. | $4.12M | 200,000 |
| NLNKEURNewLink Genetics Corporation | $3.67M | 500,000 |
| Nabriva Therapeutics plc | $3.67M | 350,000 |
| OVIDOvid Therapeutics Inc. | $3.50M | 333,333 |
| NVAXNovavax, Inc. | $2.30M | 2,000,000 |
| ARGXargenx SE | $2.12M | 100,000 |
| TENXTenax Therapeutics, Inc. | $98.00K | 132,974 |
Get alerts when BAKER BROS. ADVISORS LP files new 13F holdings.